BiotechTube
Home/Signpath Pharma/Kai P. Larson, J.D.
KP

Kai P. Larson, J.D.

President, CEO

Signpath Pharma

Therapeutic Areas

OncologyCardiology

Signpath Pharma Pipeline

DrugIndicationPhase
LipoCurc™Glioblastoma (First-line treatment)Phase 2
SPP4040 (CorreQT Platform)Prevention of drug-induced cardiotoxicityPreclinical

Leadership Team at Signpath Pharma

JP
Jonathan Plehn, M.D.
Vice President, Cardiology, Chief Medical Officer
View full Signpath Pharma profile